Akoya to Report Fourth Quarter and Full Year 2022 Financial Results on March 6th, 2023 and Participate at Two Upcoming Investor Conferences
Akoya Biosciences, Inc. (Nasdaq: AKYA) will announce its financial results for Q4 and full year 2022 after market close on March 6, 2023. A conference call will follow at 5:00 p.m. ET for discussion. Interested investors must register online. CEO Brian McKelligon will also participate in the BTIG MedTech and Cowen Healthcare Conferences.
- Scheduled release of Q4 and full year 2022 financial results on March 6, 2023.
- CEO's participation in investor conferences may boost investor interest.
- None.
MARLBOROUGH, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2022 after the market close on Monday, March 6th, 2023. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.
Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.
Akoya also announced that Brian McKelligon, CEO, will be participating in two upcoming investor conferences.
- BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- 43rd Annual Cowen Healthcare Conference
Tuesday, March 7th at 2:10 p.m. ET
A live webcast of the 43rd Annual Cowen Healthcare Conference will be available on the “Investors” section of the Akoya website https://investors.akoyabio.com/.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.
Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com
Media Contact:
Christine Quern
(617) 650-8497
media@akoyabio.com
FAQ
When will Akoya Biosciences announce its Q4 2022 financial results?
What time is the Akoya Biosciences conference call?
Who will represent Akoya at upcoming investor conferences?
